INVESTOR ALERT: Investigation on Behalf of AcelRx Pharmaceuticals, Inc. Shareholders Announced by Glancy Binkow & Goldberg LLP
September 29 2014 - 10:40AM
Business Wire
Glancy Binkow & Goldberg LLP announces that it is
investigating potential claims on behalf of purchasers of the
securities of AcelRx Pharmaceuticals, Inc. (“AcelRx” or the
“Company”) (NASDAQ:ACRX) concerning possible violations of federal
securities laws. The investigation focuses on certain statements
issued by AcelRx between December 2, 2013 and September 26, 2014,
concerning the Company’s operations and financial prospects.
Please contact Lesley Portnoy at (646) 539-8980, or at
shareholders@glancylaw.com to discuss this matter. If you inquire
by email, please include your mailing address, telephone number and
number of shares purchased.
AcelRx is a development stage specialty pharmaceutical company,
focused on the development and commercialization of therapies for
the treatment of acute and breakthrough pain. The investigation is
related to the Company’s September 26, 2014, announcement that the
Company’s New Drug Application (NDA) for Zalviso™ (sufentanil
sublingual tablet system) will qualify as a Class 2 resubmission
with a review period of six months, and AcelRx is targeting
resubmission of the NDA for first quarter 2015 or later, subject to
feedback from the FDA.
The Company previously announced in a July 28, 2014, regulatory
filing that it anticipated resubmitting the NDA by the end of 2014,
after receiving a Complete Response Letter from the FDA requesting
additional information on the Zalviso System concerning proper use
of the device, optical system errors, changes to the instructions
for use of the device, and submission of additional data to support
the shelf life of the product.
Following the September 26, 2014, disclosure, AcelRx shares
dropped nearly 20%, or $1.31 per share, on extremely heavy
volume.
If you purchased AcelRx securities between December 2, 2013 and
September 26, 2014, if you have information, or would like to learn
more, or have any questions concerning this announcement or your
rights or interests with respect to these matters, please contact
Lesley Portnoy, Esquire, of Glancy Binkow & Goldberg LLP, 1925
Century Park East, Suite 2100, Los Angeles, California 90067 at
(646) 539-8980, Toll Free at (888) 773-9224, by e-mail to
shareholders@glancylaw.com, or visit our website at
http://www.glancylaw.com. If you inquire by email please include
your mailing address, telephone number and number of shares
purchased.
This press release may be considered Attorney Advertising in
some jurisdictions under the applicable law and ethical rules.
Glancy Binkow & Goldberg LLP, Los Angeles, CALesley
Portnoy646-539-8980888-773-9224shareholders@glancylaw.comwww.glancylaw.com
AcelRX Pharmaceuticals (NASDAQ:ACRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
AcelRX Pharmaceuticals (NASDAQ:ACRX)
Historical Stock Chart
From Apr 2023 to Apr 2024